A Study of MG7 Redirected Autologous T Cells for Advanced MG7 Positive Liver Metastases(MG7-CART)

Liver Metastases Clinical Trial

Official title:

An Open-label, Uncontrolled, Single-arm Pilot Study to Evaluate Safety and Efficacy of Intratumoral Delivery Mediated MG7-targeted Chimeric Antigen Receptor T Cells in Advanced MG7 Positive Liver Metastases

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02862704
• Other study ID #: MG7-CART
• Status: Recruiting
• Phase: Phase 1/Phase 2
• First received: August 7, 2016
• Last updated: August 8, 2016
• Start date: June 2016
• Est. completion date: December 2017

Study information

• Verified date: August 2016
• Source: Xijing Hospital
• Contact: Yongzhan Nie, Doctor
• Email: yongznie[@]fmmu.edu.cn
• Is FDA regulated: No
• Health authority: China: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to collect the data on the safety and potential effectiveness of intra-tumor injection of MG7-CART cells under ultrasound guidance in patients with liver metastases expressing MG7 positively.

Description:

Designer T cells are prepared by PBMC which from patients by leukapheresis, and then activated and re-engineered to express chimeric antigen receptors (CARs) specific for MG7, which is a glycosylated protein of CEA. Cells are expanded in culture and returned to the participant by intra-tumor injection at the dose of (1-6)×108 CAR positive T cells. The cells perfusion process would last for 1min to 2min. The dose of 1.5 grams/m2 of cyclophosphamide will be given two days before CART cell infusion.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: December 2017
• Est. primary completion date: May 2017
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 69 Years

Eligibility

Inclusion Criteria:

• MG7 expression positive by histologically confirmed;

• Aged between 18 and 69;

• Persistent cancer after at least one prior standard of care chemotherapy, has no willing for surgery or cannot be suitable for surgery patients;

• Tumor is too big to surgical resection;

• Life expectancy greater than 4 months;

• Satisfactory organ and bone marrow function as defined by the following: (1) creatinine <1.5mg/dl; (2) cardiac ejection fraction of >55%; (3) hemoglobin>9g/dl, bilirubin 2.0×the institution normal upper limit;

• Without bleeding disorder or coagulation disorders;

• Dont allergy to Radiocontrast agent;

• Birth control;

• Adequate venous access for apheresis, and no other contraindications for leukapheresis;

• Voluntary informed consent is given.

Exclusion Criteria:

• Pregnant or lactating women;

• Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary;

• Patients in the situation of: (1) 30 days before apheresis is still in the period of other antitumor drug observation; (2) patient dont recuperate from earlier acute adverse influence brought by any treatments accepted before;

• Four weeks before recruit accepted radiation therapy;

• Previously treatment with any gene therapy products;

• Feasibility assessment during screening demonstrates<30% transduction of target lymphocytes, or insufficient expansion (<5-fold) in response to CD3/CD28 costimulation;

• Any serious, uncontrolled diseases (including, but not limit to, unstable angina pectoris, congestive heart failure, grade III or IV cardiac disease, serious arrhythmia, liver and kidney disorders or metabolic diseases, CNS diseases);

• Patient with severe acute hypersensitive reaction;

• Taking part in other clinical trials;

• Study leader considers not suitable for this tiral.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Liver Metastases
• Liver Neoplasms
• Neoplasm Metastasis

Intervention

Biological:
• MG7-CART
Ultrasound-guided intra-tumor injection as the route of T cell delivery, so that more T cells gathered at the tumor site, less migrate to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And MG7-CART is a 2nd CAR, with MG7 as the target protein, 4-1BB as co- stimulator

Locations

Country	Name	City	State
China	Xijing Hospital of Digestive Diseases	Xi'an	Shaanxi

Sponsors (2)

Lead Sponsor	Collaborator
Xijing Hospital	Shanghai GeneChem Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients with adverse event	adverse event is evaluated with CTCAE, version 4.0	6 weeks	Yes
Secondary	Number of patients with tumor response	summarize tumor response by overal response rates	8 weeks	No
Secondary	Detection of transferred T cells in the circulation using quantitative -PCR		8 weeks	No